Filing Flows › Precision Biosciences (DTIL) › Q2 FY25
Precision Biosciences (DTIL) Q2 FY25 earnings results (second quarter fiscal 2025)
10-K filed Mar 26, 2025
Precision Biosciences (DTIL) reported revenue of $638K for the second quarter fiscal 2025 (Q2 FY25), -91% from a year earlier and +11% from the quarter before.
Precision Biosciences, Q2 FY25: revenue $638K (-91% year over year), net loss $17.7M, operating cash flow −$18.7M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $638K | +11% | -91% |
| Operating profit | −$24.8M | — | — |
| Net earnings | −$17.7M | — | — |
| Operating cash flow | −$18.7M | — | — |
What changed
Revenue was $638K in Q2 FY25, down 91% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $24.8M, an operating margin of -3894.4%. Total costs grew 16% against a revenue fall of 91%. The fastest-growing cost line was Research & development (+19%). The quarter ended with a net loss of $17.7M, wider than the previous quarter's $16.4M loss. Non-operating items added $7.1M, -40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$18.7M. Non-cash charges added back $454K of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items used $5.0M. Capital expenditures of $97K exceeded it, leaving free cash flow of −$18.8M.
Questions
What was Precision Biosciences' revenue in the second quarter fiscal 2025?
Precision Biosciences (DTIL) reported revenue of $638K for the second quarter fiscal 2025 (Q2 FY25), -91% from a year earlier and +11% from the quarter before.